Adaptive Biotechnologies Navigates Record Performance and Strategic Shift

Adaptive Biotechnologies finds itself at a critical juncture, simultaneously celebrating exceptional financial performance while announcing the conclusion of a major long-term collaboration. This dual narrative has created a complex investment thesis, leaving the market to weigh impressive operational results against a significant change in strategic direction.

The company’s operational achievements in the second quarter of 2025 were particularly noteworthy. Total revenue surged by 36 percent to $58.9 million, with the core minimal residual Read more...